Glucocorticoids for IgA nephropathy—pro

Since IgA nephropathy (IgAN) was first described in 1968 by Jean Berger, supportive lifestyle measures and blood pressure lowering agents, especially renin-angiotensin system inhibitors (RASi), have become first-line treatment. Despite this, a substantial risk of progression remains even when these therapies are optimally employed.1 This is important as these supportive therapies, and more recently sodium-glucose cotransporter-2 inhibitors,2 do not address the underlying cause of IgAN.